國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Advances in host-directed therapies ...

Gennaro, Maria Laura.

Advances in host-directed therapies against tuberculosis

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Advances in host-directed therapies against tuberculosisedited by Petros C. Karakousis, Richard Hafner, Maria Laura Gennaro.
其他作者:	Karakousis, Petros C.
出版者:	Cham :Springer International Publishing :2021.
面頁冊數:	xiii, 332 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
標題:	TuberculosisImmunotherapy.
電子資源:	https://doi.org/10.1007/978-3-030-56905-1
ISBN:	9783030569051$q(electronic bk.)

Advances in host-directed therapies against tuberculosis
Advances in host-directed therapies against tuberculosis[electronic resource] /edited by Petros C. Karakousis, Richard Hafner, Maria Laura Gennaro. - Cham :Springer International Publishing :2021. - xiii, 332 p. :ill., digital ;24 cm.

This book discusses specific immune cell regulatory pathway(s), immune cell types, or other mechanisms involved in host responses to tuberculosis that can be potentially targeted for host-directed therapy (HDT) The pathways/mechanisms investigated are either protective - thus calling for pathway/factor enhancing drugs - or maladaptive - thus calling for pathway/factor inhibitory drugs. Discovery and development (pre-clinical and clinical) of candidate HDT agents will also be elucidated, as well as approaches for HDT of other diseases. The benefit to the reader will derive from learning about the biology of multiple host pathways involved in health and disease, how these pathways are disrupted or dysregulated during tuberculosis, and which druggable targets exist in these pathways. This book provides the reader with a roadmap of current and future directions of HDT against tuberculosis. Since the host pathways/factors involved in protective or maladaptive responses to tuberculosis are not disease-specific, information learned from the context of tuberculosis likely will be relevant to other infectious and non-infectious diseases.

ISBN: 9783030569051$q(electronic bk.)

Standard No.: 10.1007/978-3-030-56905-1doiSubjects--Topical Terms:

888961
Tuberculosis
--Immunotherapy.

LC Class. No.: RC311.3.C45

Dewey Class. No.: 616.995

Advances in host-directed therapies against tuberculosis
LDR:02166nmm a2200313 a 4500 001 596240
003 DE-He213
005 20201203214622.0
006 m d
007 cr nn 008maaau
008 211013s2021 sz s 0 eng d
020 $a 9783030569051$q(electronic bk.)
020 $a 9783030569044$q(paper)
024 7 $a 10.1007/978-3-030-56905-1 $2 doi
035 $a 978-3-030-56905-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC311.3.C45
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
072 7 $a MJCM $2 thema
082 0 4 $a 616.995 $2 23
090 $a RC311.3.C45 $b A244 2021
245 0 0 $a Advances in host-directed therapies against tuberculosis $h [electronic resource] / $c edited by Petros C. Karakousis, Richard Hafner, Maria Laura Gennaro.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a xiii, 332 p. : $b ill., digital ; $c 24 cm.
520 $a This book discusses specific immune cell regulatory pathway(s), immune cell types, or other mechanisms involved in host responses to tuberculosis that can be potentially targeted for host-directed therapy (HDT) The pathways/mechanisms investigated are either protective - thus calling for pathway/factor enhancing drugs - or maladaptive - thus calling for pathway/factor inhibitory drugs. Discovery and development (pre-clinical and clinical) of candidate HDT agents will also be elucidated, as well as approaches for HDT of other diseases. The benefit to the reader will derive from learning about the biology of multiple host pathways involved in health and disease, how these pathways are disrupted or dysregulated during tuberculosis, and which druggable targets exist in these pathways. This book provides the reader with a roadmap of current and future directions of HDT against tuberculosis. Since the host pathways/factors involved in protective or maladaptive responses to tuberculosis are not disease-specific, information learned from the context of tuberculosis likely will be relevant to other infectious and non-infectious diseases.
650 0 $a Tuberculosis $x Immunotherapy. $3 888961
650 0 $a Immunotherapy $x Methods. $3 888962
650 1 4 $a Immunology. $3 189152
650 2 4 $a Infectious Diseases. $3 274275
650 2 4 $a Pharmacotherapy. $3 615025
700 1 $a Karakousis, Petros C. $3 888958
700 1 $a Hafner, Richard. $3 888959
700 1 $a Gennaro, Maria Laura. $3 888960
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-030-56905-1
950 $a Biomedical and Life Sciences (SpringerNature-11642)